References
- Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerBase no. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2013 [cited 2014 Aug 17]. Available from: http://globocan.iarc.fr/Pages/references.aspx
- Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Heal [Internet]. 2010;46(4 Suppl):S20–6. Elsevier Ltd. DOI:10.1016/j.jadohealth.2010.01.016
- Domingo EJ, Noviani R, Noor MRM, et al. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine [Internet]. 2008 Aug 19 [cited 2014 Aug 20];26 Suppl 1:M71–79. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18945416
- Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer [Internet]. 2003 Jan 13 [cited 2014 Jul 14];88(1):63–73. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2376782&tool=pmcentrez&rendertype=abstract
- Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci [Internet]. 2006;110(5):525–541. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16597322
- A primer on HPV types [Internet]. Available from: http://www.thehpvtest.com/about-hpv/high-and-low-risk-hpv-types/?LanguageCheck=1 (accessed on Apr 12, 2015)
- Wong MCS, Lee A, Ngai KLK, et al. Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong. PLoS One. 2013;8(8):1–10.
- Marcellusi A, Capone A, Favato G, et al. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian Collaborative Study Group. Clin Ther [Internet]. 2015;37(1):156–167.e4. Elsevier. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25487083
- WHO. Human papillomavirus vaccines: WHO position paper, October 2014. World Heal Organ Wkly Epidemiol Rec [Internet]. 2014;89(43):465–492. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24707510
- Nelson R EU recommends approval of Gardasil 9 vaccine [Internet]. 2015 [cited 2015 Apr 20]. Available from: http://www.medscape.com/viewarticle/562858_print
- Mccormack PL, Joura EA. Quadrivalent human papillomavirus vaccine (Gardasil Ò) genital lesions, genital cancer and genital warts in women. Drugs. 2010;70(18):2449–2474.
- Muñoz N, Manalastas R, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–1957.
- fda-approves-mercks-hpv-vaccine-gardasil9-prevent-cancers-an @ www.mercknewsroom.com [Internet]. Available from: http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-hpv-vaccine-gardasil9-prevent-cancers-an (accessed on Apr 17, 2015)
- Malagón T, Drolet M, Boily M-C, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis [Internet]. 2012 Oct [cited 2014 Sep 1];12(10):781–789. Elsevier Ltd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22920953
- Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086.
- Gefenaite G, Smit M, Nijman HW, et al. Comparatively low attendance during human papillomavirus catch-up vaccination among teenage girls in the Netherlands: insights from a behavioral survey among parents. BMC Public Health [Internet]. 2012;12(1):498.
- LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Heal Organ. 2011;89(11):821–830b.7.
- Pfizer. The burden of cancer in Asia - Liver. Washington, DC: Pfizer Facts; 2008.
- The World Bank. Country and lending groups [Internet]. 2014 [cited 2016 Jan 8]. Available from: http://data.worldbank.org/about/country-and-lending-groups#High_income
- The World Bank. GDP per capita (current US$) [Internet]. 2016 [cited 2016 Jan 8]. Available from: http://data.worldbank.org/indicator/NY.GDP.MKTP.KD.ZG
- Moore MA, Tajima K. Cervical cancer in the Asian pacific-epidemiology, screening and treatment. Asian Pac J Cancer Prev. 2003;5:349–361.
- Jhpiego. Jhpiego in Thailand [Internet]. 2003 [cited 2015 Apr 25]. Available from: https://www.jhpiego.org/where-we-work/thailand/
- Pooripussarakul S, Riewpaiboon A, Bishai D, et al. What criteria do decision makers in Thailand use to set priorities for vaccine introduction? BMC Public Health [Internet]. 2016;16:684. BMC Public Health. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27484123
- Amfar. Cervical Cancer, Human Papillomavirus (HPV), and HPV Vaccines in Southeast Asia. 2016 November.
- GAVI. Lao people’s democratic republic (the) [Internet]. 2016 [cited 2016 Sep 13]. Available from: http://www.gavi.org/country/lao-pdr/
- GAVI. Lao PDR first South East Asian nation to introduce pneumococcal and cervical cancer vaccines with GAVI support [Internet]. 2013 [cited 2016 Sep 13]. Available from: http://www.gavi.org/library/news/press-releases/2013/lao-first-south-east-asian-nation-to-introduce-pneumococcal-and-cervical-cancer-vaccines-with-gavi-support/
- RESULTS Australia. One year on, HPV vaccines protecting Lao girls [Internet]. 2014 [cited 2016 Sep 13]. Available from: http://www.results.org.au/one-year-on-hpv-vaccines-protecting-lao-girls/
- Duclos P. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine [Internet]. 2010;28(Suppl 1):A18–25. World Health Organization. DOI:10.1016/j.vaccine.2010.02.027
- Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
- Garrido MV, Gerhardus A, Røttingen J-A, et al. Developing health technology assessment to address health care system needs. Health Policy (New York). 2010;94:196–202.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (reprinted from annals of internal medicine). Phys Ther. 2009;89(9):873–880.
- Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–Explanation and elaboration: a report of the ISPOR Health Economic Evaluations Publication Guidelines Task Force. Value Heal. 2013;16:231–250.
- Sachs JD. Macroeconomics and health: investing in health for economic development [Internet]. Geneva; 2001 Jun. Available from: http://www.nature.com/doifinder/10.1038/nm0602-551b (accessed on Apr 24, 2015)
- Development Indicator Unit. Purchasing power parities (PPP) conversion factor, local currency unit to international dollar [Internet]. New York: United Nation; 2014. Available from: http://mdgs.un.org/unsd/mdg/SeriesDetail.aspx?srid=699
- Guerrero AM, Genuino AJ, Santillan M, et al. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines. BMC Public Health [Internet]. 2015;15(1):730. BMC Public Health. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84938840256&partnerID=tZOtx3y1
- Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics [Internet]. 2011 Sep;29(9):781–806. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21838332
- Termrungruanglert W, Havanond P, Khemapech N, et al. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Heal [Internet]. 2012;15(1 Suppl):S29–34. Elsevier Inc. DOI:10.1016/j.jval.2011.11.007
- Sharma M, Ortendahl J, van der Ham E, et al. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG [Internet]. 2012 Jan [cited 2014 Sep 16];119(2):166–176. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21481160
- Lee VJ, Tay SK, Teoh YL, et al. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health [Internet]. 2011;11(1):203. BioMed Central Ltd. Available from: http://www.biomedcentral.com/1471-2458/11/203%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/21453537%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3082243
- Aljunid S, Zafar A, Saperi S, et al. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination. Asian Pac J Cancer Prev. 2010;11(6):1551–1559.
- Ezat S, Puteh W, Hospital E, et al. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pacific J Cancer Prev. 2010;11(August 2015):79–90.
- Ezat S, Aljunid S. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia. Asian Pacific J Cancer Prev. 2010;11:943–951.
- Kim JJ, Kobus KE, Diaz M, et al. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine [Internet]. 2008 Jul 29 [cited 2014 Sep 19];26(32):4015–4024. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18602731
- Goldie SJ, O’Shea M, Campos NG, et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26(32):4080–4093.
- Zhang L, Lovatel R, Nicolete D, et al. Empiric antibiotic therapy in children with community-acquired pneumonia. Indian Pediatr. 2008;45:554–558.
- Chaikledkaew U, Kittrongsiri K. Guidelines for health technology assessment in THailand (second edition)-the development process. J Med Assoc Thail. 2014;97(Suppl 5).
- Vet JNI, Kooijman JL, Henderson FC, et al. Single-visit approach of cervical cancer screening: see and treat in Indonesia. Br J Cancer [Internet]. 2012 Aug 21 [cited 2014 Sep 3];107(5):772–777. Nature Publishing Group. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3425980&tool=pmcentrez&rendertype=abstract
- Longatto-Filho A, Naud P, Derchain SF, et al. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology. Virchows Arch [Internet]. 2012 Jun [cited 2014 Jun 16];460(6):577–585. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22562132
- Seto K, Marra F, Raymakers A, et al. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs [Internet]. 2012 Mar 26;72(5):715–743. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22413761
- Levin A, Wang SA, Levin C, et al. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PLoS One. 2014;9:6.
- Graham JE, Mishra A. Global challenges of implementing human papillomavirus vaccines. Int J Equity Health [Internet]. 2011;10(1):27. BioMed Central Ltd. Available from: http://www.equityhealthj.com/content/10/1/27
- Drummond MF, Richardson S, O’Brien BJ, et al. Users â€TM guides to the medical literature XIII. How to use an article on economic analysis of clinical practice. J Am Med Assoc. 1997;277(19):1552–1557.
- Aponte-González J, Fajardo-Bernal L, Diaz J, et al. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One [Internet]. 2013 Jan [cited 2014 Sep 16];8(11):e80639. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3832449&tool=pmcentrez&rendertype=abstract
- Setiawan D, Dolk FC, Suwantika AA, et al. Cost utility analysis of human papillomavirus vaccination and cervical screening on cervical cancer patient in Indonesia. Value Heal Reg Issues. 2016;9:84–92.
- de Kok IMCM, Van Ballegooijen M, Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst [Internet]. 2009 Aug 5 [cited 2014 Aug 14];101(15):1083–1092. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19571256
- Liu P-H, Hu F-C, Lee P-I, et al. Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. BMC Health Serv Res [Internet]. 2010 Jan;10:11. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2822833&tool=pmcentrez&rendertype=abstract
- Setiawan D, Luttjeboer J, Westra TA, et al. The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective. Expert Rev Vaccines [Internet]. 2015;14(4):589–604. Available from: http://informahealthcare.com/doi/abs/10.1586/14760584.2014.990386
- Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis [Internet]. 2008 Feb;14(2):244–251. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2600200&tool=pmcentrez&rendertype=abstract
- Brisson M, Laprise JF, Drolet M, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. Vaccine. 2013;31(37):3863–3871.
- Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Bmj. 2011;343(Sep27 1):d5775–d5775.
- Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health. 2010;20(2):213–219.
- Demarteau N, Tang C-H-H, Chen H-C-C, et al. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Heal [Internet]. 2012 [cited 2014 Aug 20];15(5):622–631. Elsevier Inc. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22867770
- Capri S, Gasparini R, Panatto D, et al. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles. Gynecol Oncol [Internet]. 2011;121(3):514–521. Elsevier Inc. DOI:10.1016/j.ygyno.2011.01.029
- Burger EA, Sy S, Nygård M, et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One [Internet]. 2014 Jan [cited 2014 Sep 19];9(3):e89974. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3961226&tool=pmcentrez&rendertype=abstract
- Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics. 2014;32(6):525–531.
- Laprise J-F, Drolet M, Boily M-C, et al. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. Vaccine [Internet]. 2014 Aug 12 [cited 2014 Aug 21];32:5845–5853. DOI:10.1016/j.vaccine.2014.07.099
- Schellekens MC, Dijkman A, Aziz MF, et al. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol [Internet]. 2004 Apr [cited 2014 Sep 3];93(1):49–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15047213
- Bingham A, Drake JK, Lamontagne DS. sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med. 2010;163(5):455–461.
- Jit M, Choi YH, Laprise JF, et al. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine. 2014;32(26):3237–3242.
- Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer [Internet]. 2006 Dec 4 [cited 2014 Sep 8];95(11):1459–1466. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2360730&tool=pmcentrez&rendertype=abstract
- Safaeian M, Kemp TJ, Pan DY, et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica vaccine trial. Hum Vaccines Immunother. 2013;9(7):1399–1406.
- La Vigne P Gardasil 9 vaccine prompts push for national program [Internet]. 2016 [cited 2017 Mar 5]. Available from: http://www.thevaccinereaction.org/2016/06/gardasil-9-vaccine-prompts-push-for-national-program/